Julien Capers
Vermögen: 913 268 $ am 31.10.2026
Vermögen: 913 268 $ am 31.10.2026
Julien E Capers worked as Corporate Counsel at CareDx, Inc., Associate General Counsel at Establishment Labs Holdings, Inc., and Assistant General Counsel at Zogenix, Inc. Education includes undergraduate studies at Stanford University and graduate studies at UC Davis School of Law.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
Palisade Bio, Inc.
Palisade Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a late stage biopharmaceutical company which develops therapies for acute and chronic gastrointestinal disorders 0,47 % | 19.10.2026 | 787.300 ( 0,47 % ) | 913 268 $ | 31.10.2026 |
| Unternehmen | Position | Ende |
|---|---|---|
| VERA THERAPEUTICS, INC. | General Counsel | 01.01.2026 |
| CAREDX, INC. | Corporate Officer/Principal | - |
| ESTABLISHMENT LABS HOLDINGS INC. | Corporate Officer/Principal | - |
| ZOGENIX, INC. | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 6 |
|---|---|
CareDx, Inc.
CareDx, Inc. Medical SpecialtiesHealth Technology Manufactures diagnostic test kits and provides related testing services | Health Technology |
Zogenix, Inc.
Zogenix, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets medicines | Health Technology |
Stanford University
Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
UC Davis School of Law
UC Davis School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Establishment Labs Holdings, Inc.
Establishment Labs Holdings, Inc. Medical SpecialtiesHealth Technology Designs, develops and manufactures medical products | Health Technology |
Vera Therapeutics, Inc.
Vera Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company, which focuses on development and treatments for immunological & inflammatory diseases | Health Technology |
Bitte wählen Sie Ihre Edition
Alle länderspezifischen Finanzinformationen